Accessibility and reading comfort

Text size

Light/Dark mode

Lines vertical spacing

Trouble using our website?
Contact us

RET NAT 01

In this page

Clinical Trial

NCT02575430 Completed
RET NAT 01

Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT.

Observational
Observational

Disease

Disease type

Paediatric clinical trials

Orphan drug recognition

NA

Patient type

Adult

Children

Inclusion / Exclusion

Opening date

01/12/2015

Closing date

01/03/2016

Inclusion criteria :

More

Exclusion criteria :

More

Funding

industry

Members involved

Main investigators

Dr Katarina Stingl

Representative

Germany

Low Vision Daily Life and Patients Groups (TWG5), Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

Prof. Dr. med. Karl Ulrich Bartz-Schmidt

Substitute

Germany

See more

Dr Ingeborgh VAN DEN BORN

Representative

Netherlands

Registries & Epidemiology (TWG7), Research (TWG8), Retinal Rare Eye Diseases (WG1)
See more

Pr Michael LARSEN

Representative

Denmark

Neuro-Ophthalmology Rare Diseases (WG2), Research (TWG8), Retinal Rare Eye Diseases (WG1)
Working Group Leader
See more

ERN EYE member investigating site

HCP : Principal investigators

Centre for Ophthalmology, University Eye Hospital, Tübingen, Germany

Adress

Department für Augenheilkunde Tübingen Forschungsinstitut für Augenheilkunde Elfriede-Aulhorn-Str. 7

72076 Tübingen

Germany